Related Experiment Video
Updated: Dec 5, 2025
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
9.8K
Heart transplantation and mechanical circulatory support
Om Prakash Yadava1, Vivek Rao2
1National Heart Institute, New Delhi, India.
Indian Journal of Thoracic and Cardiovascular Surgery
|October 16, 2020
Summary
This discussion covers donation after circulatory death and the role of pulsatility in mechanical circulatory support (MCS). It also compares MCS and heart transplantation as destination therapies.
Area of Science:
- Cardiovascular Surgery
- Transplantation Medicine
- Medical Technology
Background:
- Donation after circulatory death (DCD) is a critical source of organs for transplantation.
- Mechanical circulatory support (MCS) devices offer therapeutic options for end-stage heart failure.
- The role of pulsatility in MCS performance and patient outcomes requires ongoing investigation.
Purpose of the Study:
- To explore the nuances of donation after circulatory death.
- To elucidate the significance of pulsatility in mechanical circulatory support.
- To compare the efficacy and long-term outcomes of mechanical circulatory support versus heart transplantation as destination therapy.
Main Methods:
- Expert discussion and review of current literature.
- Analysis of clinical data pertaining to DCD and MCS.
- Comparative assessment of treatment strategies for advanced heart failure.
Main Results:
- The conversation highlights key considerations in DCD protocols.
- The importance of pulsatility in optimizing MCS function is emphasized.
- Current data suggests a complex interplay between MCS and heart transplant outcomes.
Conclusions:
- Donation after circulatory death remains a vital area for organ procurement.
- Further research into pulsatility in MCS may enhance device efficacy.
- The choice between MCS and heart transplant as destination therapy depends on individual patient factors and evolving technology.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
173
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
173
01:22Heart Failure VI: Adjunct Therapies
136
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
136
01:30Cardiomyopathy II: Dilated Cardiomyopathy
266
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
266
01:30Heart Failure V: Medical Management
119
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
119
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
229
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
229